Impact of Thrombus Aspiration on Clinical Outcomes in Korean Patients with ST Elevation Myocardial Infarction

Seok-Woo Seong¹, Kye Taek Ahn¹, Mijoo Kim¹, Seon Ah Jin¹, Sang Yeub Lee², Myung ho Jeong³, Jin-Ok Jeong¹,*, and Korea Acute Myocardial Infarction Registry-National Institute of Health investigators

¹Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, ²Chungbuk Regional Cardiovascular Disease Center, Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, ³Department of Internal Medicine and Heart Center, Chonnam National University Hospital, Gwangju, Korea

We evaluated whether thrombus aspiration (TA) during primary percutaneous coronary intervention (PCI) reduces adverse clinical outcomes within 30-days and 1-year periods. There is no well-designed, Korean data about the clinical impact of intracoronary TA during primary PCI in patients with ST-segment elevation myocardial infarction (STEMI). From the Korea Acute Myocardial Infarction Registry-National Institute of Health, 3749 patients with STEMI undergoing primary PCI within 12 hours (60.8±12.9 years, 18.7% women) with pre-procedural Thrombolysis in Myocardial Infarction (TIMI) flow 0, 1 in coronary angiography were enrolled between November 2011 and December 2015. The patients were divided into two groups: PCI with TA (n=1630) and PCI alone (n=2119). The primary end-point was major adverse cardiac event (MACE), defined as the composite of cardiovascular death (CVD), recurrent MI and stroke for 30-days and 1-year. TA did not diminish the risk of MACE, all-cause mortality and CVD in all patients during 30-days or 1-year. After performing the propensity score matching, TA also did not reduce the risk of MACE (Hazard ratio (HR) with 95% Confidence Interval (CI): 1.187 [0.863-1.633], p value=0.291), all-cause mortality (HR with 95% CI: 1.130 [0.776-1.647], p value=0.523) and CVD (HR with 95% CI: 1.222 [0.778-1.920], p value=0.384) during the 1-year period. In subgroup analysis, there was no benefit of clinical outcomes favoring PCI with TA. In conclusion, primary PCI with TA did not reduce MACE, all-cause mortality or CVD among the Korean patients with STEMI and pre-procedural TIMI flow 0, 1 during the 30-day and 1-year follow ups.

Key Words: Myocardial Infarction; Percutaneous Coronary Intervention; Thrombectomy

INTRODUCTION

Manual thrombus aspiration (TA) during primary percutaneous coronary intervention (PCI) reduces thrombus burden and improves markers of myocardial reperfusion in patients with acute ST-elevation myocardial infarction (STEMI).¹² However, its clinical benefits have been a controversial issue of debate. Thrombus Aspiration during Percutaneous coronary intervention in acute myocardial infarction Study (TAPAS) trial¹³ and other several studies⁴⁶ showed a mortality reduction with TA. In contrast, in 2 recent multi-center randomized trials, the Trial of Routine Aspiration Thrombectomy with PCI versus PCI Alone in Patients with STEMI (TOTAL)⁷ and the Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE)⁸ failed to show a significant reduction in clinical events including mortality. As a result, the recent guidelines did not recommend routine TA.¹⁰¹¹

There is no well-designed Korean data about the clinical impact of intracoronary TA during primary PCI in patients with STEMI. In this study, we sought to evaluate the...
clinical impact of TA during primary PCI in STEMI patients with pre-procedural Thrombolysis in Myocardial Infarction (TIMI) flow 0, 1.

MATERIALS AND METHODS

1. Study design and population
The study population was derived from the Korea Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH) from November 2011 to December 2015. The KAMIR-NIH is a prospective, multicenter, web-based observational cohort study to develop the prognostic and surveillance index of Korean patients with acute myocardial infarction (AMI) from 20 centers in Korea and has been supported by a grant from Korea Centers for Disease Control and Prevention since November 2011.

We analyzed a total of 13,516 patients with AMI undergoing primary PCI. The inclusion criteria for the current study were as follows:

1. Patients with STEMI
2. Patients who underwent coronary angiography and PCI within 12 hours of the onset of symptoms
3. Pre-procedural TIMI flow 0, 1

We, therefore, enrolled patients in the current study. The study flow diagram is shown in Fig. 1. All patients submitted the written informed consent forms for participating in the registry. Trained study coordinators at each of the participating institutions collected the data using a standardized format. Standardized definitions of all variables were determined by the steering committee board of KAMIR-NIH. The present study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the institution's human research committee.

2. Classification of coronary angiographic findings and interventional procedures
Coronary angiography findings were graded based on the ACC/AHA (American College of Cardiology/American Heart Association) classification system. This is also associated with the complexity of the lesions. Blood flow on coronary angiography was evaluated based on the TIMI flow. Primary PCI was performed according to the standard guideline.

3. Study endpoints
The primary efficacy end-points were major adverse cardiac event (MACE), defined as a composite of the cardiovascular death (CVD), myocardial infarction (MI) or stroke at 30-day and 1-year. The secondary efficacy end-points were all-cause mortality and CVD during 30-days and 1-year.

4. Statistical analysis
Continuous variables were expressed as mean±SD (SD: standard deviation) or the median and interquartile range, and they were compared using the independent t test or Mann-Whitney U test between the two groups. Categorical variables were compared with Pearson’s Chi-square or Fisher’s exact tests between the two groups. Due to the significant baseline differences between the PCI with TA group and the PCI only group, the propensity score matching method was used. Before using propensity score matching method, we performed multiple imputation procedures to fill in the missing data of several important variables such as the left ventricular ejection fraction, initial systolic blood pressure and initial heart rate. The propensity scores were estimated using a multiple logistic regression model that contained 32 covariates in Table 1. The matching ratio was 1 to 2. Model discrimination was measured using c-statistic, and calibration was assessed by the Hosmer-Lemeshow goodness-of-fit test (c-statistic: 0.647, Hosmer-Lemshow: p=0.169). The results of the multivariable models were verified using propensity score matching method. All statistical tests were 2-tailed, and a p value<0.05 was considered statistically significant. Statistical analysis was done using the SPSS version 21.0 (Statistical Package for Social Science, SPSS Inc., Chicago, IL, USA).
TABLE 1. Baseline clinical, procedural, medical characteristics between PCI alone and PCI with TA groups before and after propensity score matching

| Variables                                      | All patients | Propensity matched patients |
|------------------------------------------------|--------------|-----------------------------|
|                                                 | PCI alone    | PCI with TA                |
|                                                 | (n=2119)     | (n=1630)                   |
|                                                 | p value      | p value                    |
| Clinical variables                              |              |                            |
| Age, years                                      | 62.6±12.5    | 60.8±12.87                 | <0.001                      |
| Female gender (%)                               | 442 (20.9)   | 304 (18.7)                 | 0.101                       |
| BMI (kg/m²)                                     | 24.2±3.2     | 24.4±3.2                   | 0.014                       |
| Hypertension (%)                                | 955 (45.1)   | 730 (44.8)                 | 0.889                       |
| Dyslipidemia (%)                                | 243 (11.5)   | 171 (10.5)                 | 0.372                       |
| Diabetes mellitus (%)                          | 496 (23.4)   | 379 (23.3)                 | 0.942                       |
| Current smoking (%)                             | 963 (45.4)   | 764 (46.9)                 | 0.388                       |
| Family history of IHD (%)                      | 132 (6.2)    | 107 (6.6)                  | 0.777                       |
| Previous heart failure (%)                     | 15 (0.7)     | 15 (0.9)                   | 0.590                       |
| Previous angina (%)                            | 128 (6.0)    | 103 (6.3)                  | 0.777                       |
| Previous myocardial infarction (%)             | 129 (6.1)    | 97 (6.0)                   | 0.916                       |
| Previous stroke (%)                            | 107 (5.0)    | 78 (4.8)                   | 0.101                       |
| Laboratory data                                |              |                            |
| Creatinine clearance (Ccr)                     | 79.4±37.4    | 83.9±42.3                  | 0.001                       |
| Hemoglobin (g/dL)                              | 14.2±1.9     | 14.3±1.9                   | 0.339                       |
| LDL (mg/dL)                                    | 115.8±38.1   | 116.6±39.2                 | 0.531                       |
| HDL (mg/dL)                                    | 42.1±11.9    | 42.9±12.8                  | 0.036                       |
| TG (mg/dL)                                     | 144.6±126.8  | 147.1±120.6                | 0.549                       |
| TC (mg/dL)                                     | 183.4±44.7  | 182.4±44.9                 | 0.515                       |
| CK-MB (ng/mL)                                  | 172 (60-300) | 150 (43-300)               | 0.006                       |
| LVEF (%)                                       | 50.4±10.3    | 50.3±9.6                   | 0.811                       |
| Procedural data                                |              |                            |
| Killip class III-IV (%)                        | 342 (16.1)   | 219 (13.4)                 | 0.024                       |
| Symptom to balloon time (min)                  | 185 (124.5-290) | 178 (121-285) | 0.165                      |
| Door to balloon time (min)                     | 58 (45-73)   | 56 (45-70)                 | 0.040                       |
| SBP at admission (mmHg)                        | 124.6±32.1   | 125.8±31.8                 | 0.283                       |
| HR at admission (beat per min)                 | 75.9±20.2    | 74.1±19.8                  | 0.007                       |
| Pre-Procedural TIMI flow 0                     | 1755 (82.8)  | 1477 (90.6)                | <0.001                      |
| Post-Procedural TIMI flow 0-1                  | 25 (0.7)     | 16 (0.4)                   | 0.563                       |
| Infarct-related vessel (%)                     | <0.001       |                            |
| Left anterior descending artery                | 1101 (52.0)  | 702 (43.1)                 | 0.002                       |
| Left circumflex artery                         | 223 (10.5)   | 140 (8.6)                  | 0.136                       |
| Right coronary artery                          | 764 (36.1)   | 776 (47.6)                 | 0.473                       |
| Left main coronary artery                      | 31 (1.5)     | 12 (0.7)                   | 0.799                       |
| Diseased vessel (%)                            |              |                            |
| 1                                              | 1107 (52.2)  | 947 (58.1)                 | 1159 (56.1)                 |
| 2                                              | 612 (28.9)   | 442 (27.1)                 | 574 (27.8)                  |
| 3                                              | 321 (15.1)   | 202 (12.4)                 | 274 (13.3)                  |
| Left main isolated                             | 9 (0.4)      | 4 (0.2)                    | 0.895                       |
| Left main complex                              | 70 (3.3)     | 35 (2.1)                   | 0.356                       |
| Anterior myocardial infarction (%)             | 1132 (53.4)  | 714 (43.8)                 | <0.001                      |
| Transfemoral vascular approach (%)             | 1732 (81.7)  | 1131 (69.4)                | <0.001                      |
| ACC/AHA B2/C lesion (%)                        | 1886 (89.0)  | 1508 (92.5)                | <0.001                      |
| Index procedure (%)                            | 0.002        |                            |
| Culprit only PCI                               | 1852 (87.4)  | 1479 (90.7)                | 1846 (90.3)                 |
| Multi-vessel PCI                               | 267 (12.6)   | 151 (9.3)                  | 220 (10.7)                  |

RESULTS

1. Baseline characteristics

A total of 3749 patients were enrolled in this study. Enrolled patients were divided into 2 groups: PCI with TA group (n=1630) and PCI alone group (n=2119). The TA during PCI procedure was performed in 43.7 percent of the total patients.
Baseline characteristics of patients before and after propensity score matching were shown in Table 1. Patients in the PCI with TA group were younger and had higher body mass indexes (BMI). In laboratory data, creatinine clearance and high-density lipoprotein (HDL) levels were significantly higher in the PCI with TA group. In hemodynamic and procedural characteristics analysis, patients in the PCI with TA group had lower Killip classes, heart rates and shorter door-to-balloon time at admission. More patients in the PCI with TA group had right coronary artery disease as the infarct-related vessel and many more cases of single vessel diseases. The higher number of transfemoral vascular approaches and culprit only PCI were found in the PCI with TA group. Glycoprotein IIb/IIIa inhibitors, statin and clopidogrel were used more often in the PCI with TA group than the PCI alone group.

After propensity-score matching, the differences in clinical variables between the PCI with TA group and the PCI alone group were less significant. Higher levels of HDL and creatine kinase-MB (CK-MB) were observed in the PCI with TA group. More cases of transfemoral vascular approaches were performed in the PCI alone group. In addition, glycoprotein IIb/IIIa inhibitors were used more often in the PCI with TA group than the PCI alone group.

2. Clinical outcomes

Clinical outcomes of the 30-day and 1-year follow-up before and after propensity matching are shown in Table 2. MACE and all-cause mortality were observed in 308 (8.2%) and 271 (7.2%) patients during the 1-year follow up respectively. With respect to the primary efficacy outcome, there was no significant difference in the incidence of MACE between the PCI alone and the PCI with TA groups at the 30-day and 1-year follow up in all patients. After propensity-score matching, there were also no significant differences in the incidence of MACE between the two groups at 30-days (5.3% vs. 5.3%, adjusted HR with 95% CI: 1.342 [0.826-2.179], p value=0.235 for TA use) and 1-year (8.2% vs. 8.2%, adjusted HR with 95% CI: 1.187 [0.863-1.633], p value=0.291 for TA use). Fig. 2 shows the Kaplan-Meier curves for 1-year MACE between the PCI alone and the PCI with TA groups in propensity-matched cohorts. There was no difference between the two groups in the rate of MACE at 1-year follow-up. Furthermore, the secondary efficacy outcomes, CVD and all-cause mortality were not different between the two groups at the 30-day and 1-year follow up before and after propensity-score matching.

Hazard ratios of various subgroups were analyzed in propensity score matched patients during a 1-year follow up. The frequency of MACE did not decrease in the PCI with TA group in all subgroup analyses (Fig. 3).

DISCUSSION

The major finding of our study is that PCI with TA in patients of STEMI who underwent primary PCI within 12 hours and pre-procedural TIMI flow 0, 1 did not reduce the risk of the adverse clinical outcomes at the 1-year follow up. Moreover, there was no improvement in clinical outcomes in the various subgroup analyses.

The result of our study corresponded well with several large-scale trials. In the randomized clinical trial of TASTE, routine thrombus aspiration before PCI did not reduce 30-day mortality, rate of death from any cause or the composite of death from any cause, re-hospitalization for myocardial infarction, or stent thrombosis at 1-year. The Trial of TOTAL also pointed out that thrombus
### TABLE 2. Clinical outcomes of thrombus aspiration between PCI alone and PCI with TA groups before and after propensity score matching at 30-day and 1-year

|                       | All patients | Unadjusted HR for TA (95% CI) | Propensity-matched patients | Adjusted HR for TA (95% CI) |
|-----------------------|--------------|-------------------------------|-----------------------------|----------------------------|
|                       | PCI alone    | PCI with TA                   | p value                     | p value                    | p value                     |
|                       | N=2119, (%)  | N=1630, (%)                   |                             |                            |                            |
| 30-day                |              |                               |                             |                            |                            |
| All-cause mortality   | 113 (5.3)    | 77 (4.7)                      | 0.410                       | 0.413                      | 0.878 (0.683-1.184)         | 0.413 (0.599-1.773)         | 0.913 |
| CVD                   | 105 (5.0)    | 72 (4.4)                      | 0.485                       | 0.454                      | 0.982 (0.717-1.398)         | 0.470 (0.696-2.194)         | 0.470 |
| Stroke                | 19 (0.9)     | 16 (1.0)                      | 0.864                       | 0.796                      | 12 (0.6)                    | 12 (0.8)                    | 0.536 |
| Recurrent MI          | 13 (0.6)     | 13 (0.8)                      | 0.554                       | 0.520                      | 17 (0.8)                    | 15 (1.0)                    | 0.720 |
| Stent thrombosis      | 11 (0.5)     | 10 (0.6)                      | 0.826                       | 0.701                      | 11 (0.5)                    | 9 (0.6)                     | 0.999 |
| TVR/TLR               | 4 (0.2)      | 2 (0.1)                       | 0.703                       | 0.616                      | 4 (0.2)                     | 4 (0.3)                     | 0.730 |
| MACE                  | 117 (5.5)    | 83 (5.1)                      | 0.608                       | 0.578                      | 109 (5.3)                   | 81 (5.3)                    | 0.999 |
|                       |              |                               |                             |                            |                            |                             | 1.342 |
| 1-year                |              |                               |                             |                            |                            |                             | 0.235 |
| All-cause mortality   | 160 (7.6)    | 111 (6.8)                     | 0.408                       | 0.383                      | 150 (7.3)                   | 108 (7.1)                   | 0.825 |
| CVD                   | 131 (6.2)    | 90 (5.5)                      | 0.402                       | 0.390                      | 123 (6.0)                   | 88 (5.8)                    | 0.806 |
| Stroke                | 28 (1.3)     | 30 (1.8)                      | 0.505                       | 0.498                      | 27 (1.3)                    | 27 (1.8)                    | 0.262 |
| Recurrent MI          | 34 (1.6)     | 24 (1.5)                      | 0.791                       | 0.683                      | 33 (1.6)                    | 23 (1.5)                    | 0.826 |
| TVR and TLR           | 47 (2.2)     | 22 (1.3)                      | 0.511                       | 0.422                      | 46 (2.2)                    | 22 (1.4)                    | 0.087 |
| Stent thrombosis      | 16 (0.8)     | 13 (0.8)                      | 0.999                       | 0.939                      | 16 (0.8)                    | 12 (0.8)                    | 0.971 |
| MACE                  | 179 (8.4)    | 129 (7.9)                     | 0.589                       | 0.499                      | 170 (8.2)                   | 125 (8.2)                   | 0.959 |

PCI: percutaneous coronary intervention, TA: thrombus aspiration, CVD: cardiovascular death, MI: myocardial infarction.
Adjust included various clinical variables including age, sex, BMI, heart rate at admission, SBP at admission, HDL, Creatine clearance, Hemoglobin, symptom balloon time (min), index procedure (culprit only PCI vs. Multi-vessel PCI), use of statin, beta-blocker, RAS blocker, Glycoprotein IIb/IIIa inhibitor, LVEF.
FIG. 2. Kaplan-Meier curve of MACE at 1-year between PCI alone and PCI with TA in propensity-matched cohort. The rate of MACE at 1-year follow-up was no significant difference between the two groups.

MACE: major adverse cardiac events, PCI: percutaneous coronary intervention, TA: thrombus aspiration.

FIG. 3. Subgroup analysis: unadjusted hazard ratio (HR) for 1-year MACE in propensity score matched patients. HR of various subgroup were analyzed in propensity score matched patients during 1-year follow up. MACE was not reduced in PCI with TA group in any subgroups. HR of overall patients was adjusted result. MACE was not also reduced in PCI with TA group in overall patients.

PCI: percutaneous coronary intervention, TA: thrombus aspiration, CVD: cardiovascular death, MI: myocardial infarction, MACE: major adverse cardiovascular event, HR: hazard ratio, TIMI: Thrombolysis in Myocardial Infarction.
clinical outcomes in all patients, TA for LAD occlusion and the use of GP IIb/IIIa inhibitors with TA showed an improvement in 12-month MACE. Sim et al. also reported that manual TA during primary PCI did not improve the clinical outcomes at 12-months; manual TA was associated with a higher risk-adjusted MACE rate compared to PCI alone in patients with longer total ischemic times.

The use of glycoprotein IIb/IIIa inhibitors and manual thrombectomy has been debated in previous studies. In the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial, an intracoronary bolus infection of the glycoprotein IIb/IIIa inhibitor abciximab was effective in reducing the infarct size, whereas thrombectomy through manual aspiration was not. Reduced embolization and improved myocardial perfusion may improve clinical outcomes. A similar result was also reported in a study published in Korean, in which manual TA was not associated with reduced infarct size assessed by cardiac computed tomography. TA may not be a safe procedure and distal embolization including cerebral embolization can occur. Coronary thrombus material triggers thrombotic, inflammatory, vasoconstrictor, and other pathways. Evacuating a portion of the thrombus and plaque material resolves only a part of the pathophysiological problem. Disrupting thrombus formation pharmacologically may be more effective.

Based on the results of the INFUSE-AMI, TASTE and TOTAL trials, The 2015 ACC/AHA guidelines for management of STEMI patients has been recently revised to show that the effectiveness of selective and bailout aspiration thrombectomy in patients undergoing primary PCI is not well established (Class IIb, level of evidence C). Also, routine aspiration thrombectomy before primary PCI is not useful (Class III, level of evidence A). Routine thrombus aspiration is not recommended (Class III, level of evidence A), but in cases of large residual thrombus burden after opening the vessel with a guide wire or a balloon, thrombus aspiration may be considered in the 2017 ESC guidelines.

Our results didn’t show any benefit of TA during PCI at the 30-days and 1-year follow-ups. In addition, TA with concomitant use of glycoprotein IIb/IIIa inhibitors did not improve the clinical outcomes. These results imply that TA might have been performed more often in patients with a larger burden of thrombus or in patients with higher risk, resulting in worse clinical outcomes. Types of thrombus can affect mortality during PCI. Some studies have focused on the macroscopic appearance of the aspirated material, subdivided into white (fibrin-rich) and red (erythrocyte-rich) thrombus. White thrombus was typically found in patients with a small thrombus burden and a short ischemic time. By contrast, red thrombus tends to be found in late-presenting patients with a higher risk of distal embolization and cardiac mortality. In our study, we could not analyze the burden or the type of thrombus.

This study has several limitations. First, although it was conducted in the patients with MI registered with the KAMIR-NIH and although statistical adjustment including propensity score matching was performed, some confounding factors still existed. Second, we only used TIMI flow grading, which is a subjective categorical variable, and other predictive markers of myocardial perfusion such as corrected TIMI frame count and myocardial brush grade, were unavailable. Third, as we analyzed the events limited within one year, the study might be underpowered to demonstrate the clinical usefulness of TA in STEMI patients.

In conclusion, our study showed that TA during primary PCI as compared to PCI alone did not reduce the incidence of MACE and all-cause mortality and CVD among the Korean patients with STEMI and pre-procedural TIMI flow 0, 1 at the 30-day and 1-year follow-ups.

ACKNOWLEDGEMENTS

This research was supported by a fund (2016-ER6304-018) by Research of Korea Centers for Disease Control and Prevention and Chungnam National University 2017.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Svilas T, Vlaar PJ, van der Horst IC, Dierckx GF, de Smet BJ, van den Heuvel AF, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008;358:557-67.
2. Costopoulos C, Gorog DA, Di Mario C, Kukreja N. Use of thrombectomy devices in primary percutaneous coronary intervention: a systematic review and meta-analysis. Int J Cardiol 2013;163:229-41.
3. Vlaar PJ, Svilas T, van der Horst IC, Dierckx GF, Fokkema ML, de Smet BJ, et al. Cardiac death and reinfarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): a 1-year follow-up study. Lancet 2008;371:1915-20.
4. Sardella G, Mancone M, Bucciarelli-Ducci C, Agati L, Scardala R, Carbone I, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol 2009;53:309-15.
5. De Luca G, Dudek D, Sardella G, Marino P, Chevalier B, Zijlstra F. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur Heart J 2008;29:3002-10.
6. Burzotta F, De Vita M, Gu YL, Ishikii T, Lefèvre T, Kalsof A, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of
11 trials. Eur Heart J 2009;30:2193-203.
7. Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al.; TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 2015;372:1389-98.
8. Fröbert O, Lagerqvist B, Olivecrona GK, Gudnason T, Maeng M, et al.; TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2015;369:1587-97.
9. Lagerqvist B, Fröbert O, Olivecrona GK, Gudnason T, Maeng M, Alström P, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med 2014;371:1111-20.
10. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:1199-1269.
11. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cerek B, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2016;133:1135-47.
12. Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King SB 3rd, McCallister BD, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American College of Cardiology Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1993;88:2987-3007.
13. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999;33:1756-824.
14. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation 2008;117:296-329.
15. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee. Circulation 2008;117:261-95.
16. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J 2008;29:2989-3001.
17. Elgendy YH, Huo T, Bhatt DL, Bavry AA. Is aspiration thrombectomy beneficial in patients undergoing primary percutaneous coronary intervention? Meta-analysis of randomized trials. Circ Cardiovasc Interv 2015;8:e002258.
18. Hachinohe D, Jeong MH, Saito S, Kim MC, Cho KH, Ahmed K, et al.; Korea Acute Myocardial Infarction Registry Investigators. Clinical impact of thrombus aspiration during primary percutaneous coronary intervention: results from Korea Acute Myocardial Infarction Registry. J Cardiol 2012;59:249-57.
19. Sim DS, Jeong MH, Ahn Y, Kim YJ, Chae SC, Hong TJ, et al.; other Korea Acute Myocardial Infarction Registry (KAMIR) Investigators. Manual thrombus aspiration during primary percutaneous coronary intervention: impact of total ischemic time. J Cardiol 2017;69:428-35.
20. Bajaj NS, Ather S, Gaba S, Aggarwal H, Arora P, Ghimire G, et al. Glycoprotein IIb/IIIa inhibitors improve mortality after aspiration thrombectomy in patients with ST-segment elevation myocardial infarction. Int J Cardiol 2015;176:206-7.
21. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, et al.; INFUSE-AMI Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012;307:1817-26.
22. Sim DS, Ahn Y, Kim YH, Lee D, Seon JH, Park KH, et al. Effect of manual thrombus aspiration during primary percutaneous coronary intervention on infarct size: evaluation with cardiac computed tomography. Int J Cardiol 2013;168:4328-30.
23. Quadros AS, Cambruzzi E, Sebben J, David RB, Abelin A, Welter D, et al. Red versus white thrombi in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: clinical and angiographic outcomes. Am Heart J 2012;164:553-60.
24. van’t Hof AW, Liem A, Suryapranata H, Hoornje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zolle Myocardial Infarction Study Group. Circulation 1998;97:2302-6.
25. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.